
【Introduction】
Product Name: Human IgE Antibody (Ligelizumab, Research Use)
Catalog Number: NBR-0719
Target Name: IgE
Trade Name: Ligelizumab
Antibody Drug Description: Ligelizumab (QGE031) is a more recent humanized anti-IgE antibody developed by Novartis. It is also directed against Cε3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139 pM (as compared to the KD of omalizumab, ~6–8 nm). The first clinical results of ligelizumab treatment indicated that this antibody can reduce free-IgE and basophil FcεRI with an efficiency superior to that of omalizumab (NCT01716754).
【Description】
Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS:N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG
【Gene Information】
Gene Name: IGHE
Synonyms: N/A
Target Description: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells.
Ensembl: ENSG00000211891
Uniprot: P01854